The effect of angiotensin II on uveoscleral outflow in rabbits.

Curr Eye Res

Research Laboratories of Neuroscience and Immunology, Sankyo Company Limited, Tokyo, Japan.

Published: August 2001

Purpose: In our previous study, we showed that the AT1 receptor antagonist increased uveoscleral outflow (USF) when topically applied to the rabbit eye. However this increase was too small to demonstrate a clear physiological role for ocular angiotensin II (AII). Hence, the purpose of this study was to determine whether ocular AII influenced USF regulation, and if so, how this occurred.

Methods: USF was measured by the FITC-dextran perfusion method in albino rabbits. AII and its receptor antagonists were directly applied into the anterior chamber by adding into the perfusate and by perfusing with FITC-dextran. We also analyzed angiotensin receptors on the rabbit ciliary body membrane by a receptor binding assay with 125I-[Sar1), Ile8]-AII as a ligand.

Results: CS-088 (1 microg/ml) increased USF by 24% while AII decreased USF in a concentration-dependent manner between 10 and 500 nM. Its maximum decrease of 19% occurred at 500 nM. At this AII concentration the USF reduction was antagonized by 1 microg/ml CS-088, an AT1-receptor antagonist, but not by the same concentration of PD-123,177, an AT2-receptor antagonist. Specific 125I-[Sar1, Ile8]-AII binding to the rabbit ciliary body membranes was inhibited by CS-088 with an inhibition constant of 7.05 nM, whereas inhibition by PD-123,177 was not observed.

Conclusions: Ocular AII was indicated to attenuate USF via AT1 receptors in rabbits, however its physiological effect was not critical in IOP regulation.

Download full-text PDF

Source
http://dx.doi.org/10.1076/ceyr.23.2.139.5470DOI Listing

Publication Analysis

Top Keywords

uveoscleral outflow
8
ocular aii
8
rabbit ciliary
8
ciliary body
8
125i-[sar1 ile8]-aii
8
usf
7
aii
6
angiotensin uveoscleral
4
outflow rabbits
4
rabbits purpose
4

Similar Publications

Glaucoma is a chronic optic neuropathy that causes characteristic visual field defects and is considered one of the leading causes of irreversible vision loss worldwide. Lowering intraocular pressure is the only proven treatment for glaucoma. Medical therapy is usually the first-line treatment for open-angle glaucoma and ocular hypertension.

View Article and Find Full Text PDF

Minimally invasive glaucoma surgeries (MIGS) offer an alternative approach, aiming to be both safe and effective. Defined by their ab interno technique, which avoids creating a bleb, MIGS procedures seek to reduce intraocular pressure (IOP) by enhancing the outflow pathways of aqueous humor. Techniques include stenting, incisions, and excisions of the trabecular meshwork, canaloplasty of Schlemm's canal, and drainage implants that enhance uveoscleral outflow to the subchoroidal space.

View Article and Find Full Text PDF

Background: To evaluate the one-year safety and effectiveness of bio-interventional cyclodialysis and scleral reinforcement in open-angle glaucoma (OAG) patients undergoing cataract surgery.

Methods: An ab-interno approach was used to create a sectoral cyclodialysis in OAG patients who were prospectively followed in a consecutive case series. Subsequent visco-cycloplasty with scleral reinforcement using homologous minimally modified allograft scaffold was completed to maintain patency of the cyclodialysis reservoir and increase uveoscleral outflow.

View Article and Find Full Text PDF

[Application progress of micropulse wave transscleral laser treatment in glaucoma].

Zhonghua Yan Ke Za Zhi

December 2024

Aier Glaucoma Institute, Hunan Engineering Research Center for Glaucoma with Artificial Intelligence in Diagnosis and Application of New Materials, Changsha Aier Eye Hospital, Changsha410015, China.

Glaucoma is the leading cause of blindness worldwide, and reducing intraocular pressure is crucial to delaying its progression. This review aims to explore the application progress of micropulse wave transscleral laser treatment (mTLT) in the treatment of glaucoma. This article introduces the evolution of ciliary body destructive surgical methods, and focuses on the mechanism of mTLT in the treatment of glaucoma, including reducing aqueous humor production, increasing the uveoscleral pathway and trabecular meshwork pathway for aqueous humor outflow.

View Article and Find Full Text PDF

The glaucoma treatment paradigm is in evolution. The topical medications-first approach is limited by significant barriers such as high rates of nonadherence and side effects including ocular surface disease. The era of interventional glaucoma has seen the development of selective laser trabeculoplasty (SLT), procedural pharmaceuticals, and minimally invasive glaucoma surgeries (MIGS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!